Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

scientific article published on 25 September 2018

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJMOA1810171
P698PubMed publication ID30280657

P50authorJames Chih-Hsin YangQ37840097
Marcello TiseoQ52312493
Enriqueta FelipQ56605610
P2093author name stringNeeraj Gupta
Dong-Wan Kim
Cesare Gridelli
Frank Griesinger
Alessandro Morabito
Gee-Chen Chang
Myung-Ju Ahn
D Ross Camidge
Raffaele Califano
Sanjay Popat
Jong-Seok Lee
Scott N Gettinger
Ji-Youn Han
Sharmistha Ghosh
Alessandra Bearz
Hye Ryun Kim
Ki Hyeong Lee
Alexander Spira
Maximilian J Hochmair
Jacky Yu-Chung Li
Angelo Delmonte
David Kerstein
Rosario Garcia Campelo
Jeff Haney
P2860cites workEML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancerQ27851440
P433issue21
P407language of work or nameEnglishQ1860
P921main subjectlung cancerQ47912
crizotinibQ5186964
P304page(s)2027-2039
P577publication date2018-09-25
P1433published inThe New England Journal of MedicineQ582728
P1476titleBrigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
P478volume379

Reverse relations

cites work (P2860)
Q90412382A banner year for immunotherapy and targeted therapy
Q61449902ALK Inhibitors in the Treatment of ALK Positive NSCLC
Q89778188ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
Q104064532ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Q64102639Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
Q89497162Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
Q93075388Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
Q58616509Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
Q101136382Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
Q92611270Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Q98213088Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer
Q89725043Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Q91099817Brain metastases
Q89622190Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option
Q64256413Brigatinib is another treatment option for patients diagnosed with advanced -positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib
Q90731627Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
Q92578527Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Q92450899Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
Q89811416Current approaches to the management of brain metastases
Q91737711Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
Q90809080Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Q64089193Emerging therapies for non-small cell lung cancer
Q91981779Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Q92134606Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer
Q57048891From WCLC 2018
Q90291994From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
Q95315033Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer
Q92684950How I treat ALK-positive non-small cell lung cancer
Q91908238Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)
Q99582878Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
Q89622173Improving outcomes for brain metastases in EGFR mutated NSCLC
Q89622158Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints
Q58607883Lorlatinib: a new-generation drug for ALK-positive NSCLC
Q89837824MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Q92144036MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential
Q92326347Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
Q92134597New generation anaplastic lymphoma kinase inhibitors
Q90809086Next-generation ALK inhibitors: is the median the message?
Q98612903Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
Q94526250Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
Q97544575Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report
Q92236871Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
Q64062728Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis
Q99711973Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Q59341081Recent advances in managing brain metastasis
Q97518316Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group
Q99400360Regulation of CD47 expression in cancer cells
Q92635410Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review
Q98613555Role of imaging biomarkers in mutation-driven non-small cell lung cancer
Q93185774SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Q90719140Small molecules, big impact: 20 years of targeted therapy in oncology
Q104289124Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer
Q64067749Targeting Molecular Pathways in Intracranial Metastatic Disease
Q91895786Targeting anaplastic lymphoma kinase in neuroblastoma
Q89666580Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
Q90665244The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
Q90682094The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer
Q91709281The impact of systemic precision medicine and immunotherapy treatments on brain metastases
Q89497176The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era
Q90697039Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020
Q90688022Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists

Search more.